Literature DB >> 17314042

Novel selective human melanocortin-3 receptor ligands: use of the 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba) scaffold.

Steven Ballet1, Alexander V Mayorov, Minying Cai, Dagmara Tymecka, Kevin B Chandler, Erin S Palmer, Karolien Van Rompaey, Aleksandra Misicka, Dirk Tourwé, Victor J Hruby.   

Abstract

In search of new selective antagonists and/or agonists for the human melanocortin receptor subtypes hMC1R to hMC5R to elucidate the specific biological roles of each GPCR, we modified the structures of the superagonist MT-II (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH(2)) and the hMC3R/hMC4R antagonist SHU9119 (Ac-Nle-c[Asp-His-D-Nal(2')-Arg-Trp-Lys]-NH(2)) by replacing the His-d-Phe and His-d-Nal(2') fragments in MT-II and SHU9119, respectively, with Aba-Xxx (4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one-Xxx) dipeptidomimetics (Xxx=D-Phe/pCl-D-Phe/D-Nal(2')). Employment of the Aba mimetic yielded novel selective high affinity hMC3R and hMC3R/hMC5R antagonists.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314042      PMCID: PMC2442462          DOI: 10.1016/j.bmcl.2007.02.020

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  31 in total

1.  Structure-activity studies of the melanocortin peptides: discovery of potent and selective affinity antagonists for the hMC3 and hMC4 receptors.

Authors:  Paolo Grieco; Antonio Lavecchia; Minying Cai; Devendra Trivedi; David Weinberg; Tanya MacNeil; L H T Van der Ploeg; Victor J Hruby
Journal:  J Med Chem       Date:  2002-11-21       Impact factor: 7.446

2.  Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors.

Authors:  Malcolm J Kavarana; Dev Trivedi; Minying Cai; Jinfa Ying; Matthew Hammer; Christopher Cabello; Paolo Grieco; Guoxia Han; Victor J Hruby
Journal:  J Med Chem       Date:  2002-06-06       Impact factor: 7.446

3.  Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass.

Authors:  A S Chen; D J Marsh; M E Trumbauer; E G Frazier; X M Guan; H Yu; C I Rosenblum; A Vongs; Y Feng; L Cao; J M Metzger; A M Strack; R E Camacho; T N Mellin; C N Nunes; W Min; J Fisher; S Gopal-Truter; D E MacIntyre; H Y Chen; L H Van der Ploeg
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

4.  Discovery and in vivo evaluation of new melanocortin-4 receptor-selective peptides.

Authors:  Wouter A J Nijenhuis; John A W Kruijtzer; Nienke Wanders; Dorien H Vrinten; Keith M Garner; Wim M M Schaaper; Rob H Meloen; Willem Hendrik Gispen; Rob M Liskamp; Roger A H Adan
Journal:  Peptides       Date:  2003-02       Impact factor: 3.750

5.  Methyl 2-((succinimidooxy)carbonyl)benzoate (MSB): a new, efficient reagent for N-phthaloylation of amino acid and peptide derivatives.

Authors:  J Richard Casimir; Gilles Guichard; Jean-Paul Briand
Journal:  J Org Chem       Date:  2002-05-31       Impact factor: 4.354

Review 6.  Role of melanocortins in the central control of feeding.

Authors:  A V Vergoni; A Bertolini
Journal:  Eur J Pharmacol       Date:  2000-09-29       Impact factor: 4.432

7.  Selective, high affinity peptide antagonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro.

Authors:  M A Bednarek; T MacNeil; R N Kalyani; R Tang; L H Van der Ploeg; D H Weinberg
Journal:  J Med Chem       Date:  2001-10-25       Impact factor: 7.446

8.  Exploring the stereostructural requirements of peptide ligands for the melanocortin receptors.

Authors:  Victor J Hruby; Minying Cai; Paolo Grieco; Guoxia Han; Malcolm Kavarana; Dev Trivedi
Journal:  Ann N Y Acad Sci       Date:  2003-06       Impact factor: 5.691

9.  Solution structures of cyclic melanocortin agonists and antagonists by NMR.

Authors:  Jinfa Ying; Katalin E Kövér; Xuyuan Gu; Guoxia Han; Dev B Trivedi; Malcolm J Kavarana; Victor J Hruby
Journal:  Biopolymers       Date:  2003       Impact factor: 2.505

10.  Synthesis of N,N'-disubstituted 3-aminobenzo[c] and [d]azepin-2-ones as potent and specific farnesyl transferase inhibitors.

Authors:  Thierry Le Diguarher; Jean-Claude Ortuno; David Shanks; Nicolas Guilbaud; Alain Pierré; Eric Raimbaud; Jean-Luc Fauchère; John A Hickman; Gordon C Tucker; Patrick J Casara
Journal:  Bioorg Med Chem Lett       Date:  2004-02-09       Impact factor: 2.823

View more
  15 in total

1.  Approaches to the rational design of selective melanocortin receptor antagonists.

Authors:  Victor J Hruby; Minying Cai; Joel Nyberg; Dhanasekaran Muthu
Journal:  Expert Opin Drug Discov       Date:  2011-03-24       Impact factor: 6.098

2.  Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-3 receptor agonist versus antagonist activity.

Authors:  Bettina Proneth; Irina D Pogozheva; Federico P Portillo; Henry I Mosberg; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

Review 3.  Melanotropins as drugs for the treatment of obesity and other feeding disorders: potential and problems.

Authors:  Minying Cai; Joel Nyberg; Victor J Hruby
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

Review 4.  Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.

Authors:  Victor J Hruby; Minying Cai
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

5.  Cyclic lactam hybrid α-MSH/Agouti-related protein (AGRP) analogues with nanomolar range binding affinities at the human melanocortin receptors.

Authors:  Alexander V Mayorov; Minying Cai; Erin S Palmer; Dustin K Tanaka; James P Cain; Matthew M Dedek; Bahar Tan; Dev Trivedi; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2011-03-13       Impact factor: 2.823

Review 6.  Design of novel melanocortin receptor ligands: multiple receptors, complex pharmacology, the challenge.

Authors:  Victor J Hruby; Minying Cai; James Cain; Joel Nyberg; Dev Trivedi
Journal:  Eur J Pharmacol       Date:  2011-01-03       Impact factor: 4.432

7.  Solid-phase peptide head-to-side chain cyclodimerization: discovery of C(2)-symmetric cyclic lactam hybrid α-melanocyte-stimulating hormone (MSH)/agouti-signaling protein (ASIP) analogues with potent activities at the human melanocortin receptors.

Authors:  Alexander V Mayorov; Minying Cai; Erin S Palmer; Zhihua Liu; James P Cain; Josef Vagner; Dev Trivedi; Victor J Hruby
Journal:  Peptides       Date:  2010-08-03       Impact factor: 3.750

8.  Variation of the net charge, lipophilicity, and side chain flexibility in Dmt(1)-DALDA: Effect on Opioid Activity and Biodistribution.

Authors:  Alexandre Novoa; Sylvia Van Dorpe; Evelien Wynendaele; Mariana Spetea; Nathalie Bracke; Sofie Stalmans; Cecilia Betti; Nga N Chung; Carole Lemieux; Johannes Zuegg; Matthew A Cooper; Dirk Tourwé; Bart De Spiegeleer; Peter W Schiller; Steven Ballet
Journal:  J Med Chem       Date:  2012-11-12       Impact factor: 7.446

9.  Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 receptor.

Authors:  Hongchang Qu; Minying Cai; Alexander V Mayorov; Paolo Grieco; Morgan Zingsheim; Dev Trivedi; Victor J Hruby
Journal:  J Med Chem       Date:  2009-06-25       Impact factor: 7.446

10.  Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain.

Authors:  Karel Guillemyn; Joanna Starnowska; Camille Lagard; Jolanta Dyniewicz; Ewelina Rojewska; Joanna Mika; Nga N Chung; Valérie Utard; Piotr Kosson; Andrzej W Lipkowski; Lucie Chevillard; Pol Arranz-Gibert; Meritxell Teixidó; Bruno Megarbane; Dirk Tourwé; Frédéric Simonin; Barbara Przewlocka; Peter W Schiller; Steven Ballet
Journal:  J Med Chem       Date:  2016-04-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.